Pharmacovigilance in oncology: pattern of spontaneous notifications, incidence of adverse drug reactions and under-reporting by Visacri, Marília Berlofa et al.
*Correspondence: P. Moriel. Departamento de Patologia Clínica, Fa-
culdade de Ciências Médicas, Universidade Estadual de Campinas. Rua 
Alexander Fleming, 105, 13083-881 – Campinas – SP, Brasil. E-mail: 
morielpa@fcm.unicamp.br
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 50, n. 2, apr./jun., 2014
http://dx.doi.org/10.1590/S1984-82502014000200021
Pharmacovigilance in oncology: pattern of spontaneous notifications, 
incidence of adverse drug reactions and under-reporting
Marília Berlofa Visacri1, Cinthia Madeira de Souza1, Rafaela Pimentel2, Cristina Rosa Barbosa3, 
Catarina Miyako Shibata Sato4, Silvia Granja4, Mécia de Marialva4, Carmen Silvia Passos Lima5, 
Priscila Gava Mazzola1, Patrícia Moriel1,*
1Department of Clinical Pathology, School of Medical Sciences, State University of Campinas, Campinas, SP, Brazil, 2Institute of 
Biology, State University of Campinas, Campinas, SP, Brazil, 3Chemotherapy Preparation Unit, Hospital of Clinics of State University 
of Campinas, Campinas, SP, Brazil, 4Pharmacy Service, Hospital of Clinics of State University of Campinas, Campinas, SP, Brazil, 
5Department of Clinical Medicine, School of Medical Sciences, State University of Campinas, Campinas, SP, Brazil
The high toxicity and narrow therapeutic window of antineoplastic agents makes pharmacovigilance 
studies essential in oncology. The objectives of the current study were to analyze the pattern of spontaneous 
notifications of adverse drug reactions (ADRs) in oncology patients and to analyze the incidence of ADRs 
reported by outpatients on antineoplastic treatment in a tertiary care teaching hospital. To compose the 
pattern of ADR, the notification forms of reactions in oncology patients in 2010 were reviewed, and the 
reactions were classified based on the drug involved, mechanism, causality, and severity. To evaluate 
the incidence of reactions, a questionnaire at the time of chemotherapy was included, and the severity 
was classified based on the Common Terminology Criteria. The profiles of the 10 responses reported to 
the Pharmacovigilance Sector were type B, severe, possible, and they were primarily related to platinum 
compounds and taxanes. When the incidence of reactions was analyzed, it was observed that nausea, 
alopecia, fatigue, diarrhea, and taste disturbance were the most frequently reported reactions by oncology 
patients, and the grade 3 and 4 reactions were not reported. Based on this analysis, it is proposed that 
health professionals should be trained regarding notifications and clinical pharmacists should increasingly 
be brought on board to reduce under-reporting of ADRs.
Uniterms: Pharmacovigilance. Oncovigilance. Drugs/adverse reactions. Adverse drug reactions/under-
reporting. Adverse drug reactions/Spontaneous notification. Clinical pharmacy.
Estudos de farmacovigilância são imprescindíveis em oncologia, pois os antineoplásicos possuem alta 
toxicidade e estreita janela terapêutica. Os objetivos deste estudo foram analisar o perfil das notificações 
espontâneas de reações adversas a medicamentos (RAM) em pacientes oncológicos e a incidência de 
RAM ao tratamento antineoplásico em um hospital terciário e universitário. Para compor o perfil de 
RAM, revisaram-se os formulários de notificação de reações em pacientes oncológicos do ano de 2010 
e classificaram-se as reações conforme o medicamento envolvido, mecanismo, causalidade e gravidade. 
Para avaliar a incidência de reações, aplicou-se um questionário no momento da quimioterapia e a 
gravidade foi classificada pelos Critérios Comuns de Toxicidade. Apenas 10 reações foram notificadas 
ao Setor de Farmacovigilância, cujo perfil encontrado foi tipo B, grave, possível, e foram principalmente 
relacionadas aos compostos de platina e taxanos. Na análise da incidência das reações, observou-se que 
náusea, alopecia, fadiga, diarreia e distúrbio do paladar foram as reações mais frequentes relatadas por 
pacientes oncológicos, e as reações grau 3 e 4 não foram notificadas. De acordo com essas análises, 
propõe-se que os profissionais da saúde sejam treinados quanto às notificações e que farmacêuticos 
clínicos sejam cada vez mais inseridos neste contexto para redução da subnotificação de RAM.
Unitermos: Farmacovigilância. Oncovigilância. Medicamentos/reações adversas. Antineoplásicos/
reações adversas. Reações adversas a medicamentos/subnotificação. Reações adversas a medicamentos/
notificação espontânea. Farmácia clínica.
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INTRODUCTION
Pharmacovigilance is defined as a set of activities 
designed to identify and evaluate the effects of the acute and 
chronic use of pharmacological treatments in the population 
or subgroups exposed to specific treatments (Laporte, 
Carné, 1993). However, this concept has changed over the 
decades, which reflects the development of the associated 
activities. Thus, in 2002, the World Health Organization 
(WHO) expanded the definition of pharmacovigilance to 
science and activities related to the detection, assessment, 
understanding, and prevention of adverse effects or any drug 
related problem (WHO, 2002). The most frequently used 
pharmacovigilance model, the spontaneous notification 
of adverse drug reactions (ADRs), has proven inefficient 
because it usually results in under-reporting (Zancan et 
al., 2009). In several countries, pharmacists involved in 
pharmacovigilance have played an important role in the 
notification of suspected ADR by providing information and 
instructions on the safe and appropriate use of medicines, 
in addition to reducing the prevalence of ADRs and under-
reporting (Van-Grootheest, Jong-Van Den Berg, 2005). This 
is possible because the pharmacists who directly advise 
patients, especially within the context of pharmaceutical 
care, are more likely to detect ADRs.
Pharmacovigilance studies are essential in oncology. 
Antineoplastic agents are well studied and are extremely 
beneficial in cancer treatment, but they are used with 
caution due to their high toxicity and narrow therapeutic 
window (Gandhi et al., 2005). ADRs are so common and 
predictable in oncology that they came around to being 
accepted as an inevitable component of the treatment 
(Lau et al., 2004). Thus, onco-pharmacovigilance was 
developed, which is a subsystem of monitoring drugs 
derived from pharmacovigilance to monitor ADRs to 
cytotoxic antineoplastic drugs (Cobert, Biron, 2002; 
Albini et al., 2012).
Pharmacists specialized in oncology are responsible 
for a wide variety of functions, including monitoring, 
notification, prevention, and relief of reactions associated 
with chemotherapy (Liekweg et al., 2004). In a Japanese 
study, pharmacists were responsible for the prevention 
and treatment of emesis, peripheral neuropathy, hand–
foot syndrome, mucositis, localized pain, constipation, 
vascular pain, allergy, hyperglycemia, diarrhea and other 
conditions (Iihara et al., 2011). Lau et al., (2004) studied 
the preventability of reactions in oncology patients and 
found that 53% of the reactions such as alopecia cannot 
be prevented, whereas 45% and 2% of the reactions are 
probably and definitely preventable, respectively.
Studies that shows the incidence of ADRs to 
chemotherapy are scarce, which hinders the actual 
understanding of their severity and frequency of occurrence 
in clinical practice. Therefore, studies that report these 
adverse results can assist the multidisciplinary team in 
patient education and further suggest preventive procedures 
and medications. Thus, the adherence to treatment, 
clinical condition, and response to chemotherapy can be 
improved, reinforcing the existing review studies that 
suggest alternatives for the prevention and treatment of 
ADRs induced by chemotherapy (Iki, Urabe, 2000; Boige, 
Ducreax, 2001; Yoshida, 2002; Sharma et al., 2005; 
Yamamoto, Iwase, 2012).
Hence, the primary objectives of the current study 
was to analyze the pattern of spontaneous notification 
of suspected ADRs affecting oncology patients at a 
tertiary care teaching hospital, integrated with the 
Pharmacovigilance Program from the Brazilian National 
Health Surveillance Agency (ANVISA) during 2010, and 
to assess the incidence of ADRs related to antineoplastic 
treatment and the degree of toxicity reported by patients 
at the Chemotherapy Clinic.
MATERIAL AND METHODS
This is a descriptive and exploratory study in the 
field of pharmacovigilance, in which the spontaneous 
notifications of suspected ADRs affecting oncology 
patients were analyzed, the incidence of ADRs related 
to antineoplastic treatment, and the degrees of toxicity 
(Figure 1a and 1b), in a large (403 beds and outpatient 
units), tertiary care teaching hospital in the state of São 
Paulo (Hospital of Clinics, University of Campinas), 
integrated with the Pharmacovigilance Program of 
the Brazilian National Surveillance Agency Sanitary 
(ANVISA). The Research Ethics Committee of the 
institution approved the study.
Spontaneous Notifications of Suspected ADRs 
that Affected Cancer Patients
Different health professionals can notify suspected 
ADR by submitting a form to the Pharmacovigilance 
Sector of the hospital. The pharmacist reviews notifications 
to supplement the data by studying medical records, 
interviewing the professionals involved in the case, and 
monitoring patients from the point of notification to the 
resolution of the case or till their discharge from the 
hospital, to gather updated information. Subsequently, 
the pharmacist reports the reactions to ANVISA online.
It were analyzed all the notification forms on 
suspected ADR that have affected oncology patients 
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(both inpatients as outpatients) from January to December 
2010. Of the hospitalized patients, the reactions that 
occurred during the hospitalization period and that led 
to the hospital admission were studied. Reports of the 
suspected reaction in patients of both genders and of any 
age were included. The notification of suspected ADR was 
analyzed, including patient data, such as gender, age, type 
of neoplasm, comorbidities, possible risk factors, allergies, 
the description of the reaction and its start date and end, 
the drugs involved and the suspected drug (generic name, 
route of administration, dose, and posology), and the 
antineoplastic protocol.
For classification of drugs in drug groups, the 
third and fourth levels of the Anatomical Therapeutic 
Chemical Classification (ATC) (WHO, 2013) were used. 
Each reaction was characterized as follows. The reaction 
mechanism, using the classification proposed by Rawlins 
and Thompson (1998) (type A and B); causality, using 
the Naranjo Algorithm (Naranjo et al., 1981) (doubtful, 
possible, probable, and definite); and severity, according 
to Coêlho et al., (1999) (mild, moderate, severe, and fatal).
Incidence of ADRs and Degrees of Toxicity in the 
Chemotherapy Clinic
The Chemotherapy Clinic of the hospital in question 
is responsible for the intravenous antineoplastic treatment 
of patients with solid tumors, whereas gynecological 
tumors (breast, ovary, and uterus) are usually not treated 
in this clinic.
From October to November 2010, it were included 
all patients who underwent chemotherapy at the clinic 
on the day of the interview (regardless of personal 
characteristics, treatment protocol, and type of neoplasm), 
provided they agreed to answer the questionnaire and were 
not undergoing chemotherapy for the first time. Based on 
the protocols, both types of intravenous antineoplastic 
drugs (cytotoxins and monoclonal antibodies) were 
considered.
At the time of drug infusion, the patients were either 
questioned about the onset of a reaction during the session 
on the day of the interview or related to previous sessions 
of the same chemotherapy protocol. They were also 
questioned about ADRs that arise after the chemotherapy 
session (h or days) that occurred at least once during 
treatment with the same protocol. The questionnaire also 
included specific questions to assess the severity of ADRs, 
which allowed classifying them according to their degree 
of toxicity.
The following data for characterization of patients 
were collected: identification, gender, age, weight, 
height, type of neoplasm, and antineoplastic protocol. 
The reactions investigated were alopecia, dyspepsia, 
obstipation, diarrhea, taste disturbance, pain, fatigue, 
fever, insomnia, mucositis, nausea, hiccups, drowsiness, 
dizziness, tremor, and vomiting; of these, dyspepsia, 
diarrhea, fatigue, nausea, obstipation, dizziness, and 
vomiting were classified according to the degree of 
toxicity (grade 1 to 4) using the National Cancer Institute 
Common Terminology Criteria for Adverse Events 
(CTCAE) (version 3) (2011).
RESULTS
Spontaneous Notifications of Suspected ADRs 
that Affected Cancer Patients
On analyzing the spontaneous notifications of 
suspected ADR occurring in oncology outpatients and 
inpatients, 10 notifications were found, 7 of which were 
antineoplastic, and they constituted 37.0% of the total 
ADRs recorded in 2010 (Table I). The mean age was 46.6 
± 20.6 years (minimum age: 19 years, maximum age: 
70 years) and the majority patients were male (70.0%) 
(Table II). The therapeutic classes of drugs suspected 
of causing the reactions included: 3 plant alkaloids and 
other natural products (podophyllotoxin derivatives 
and taxanes) (30.0%); 3 other antineoplastic agents 
FIGURE 1 - Schematic of the study design. (A) Spontaneous 
notifications of suspected adverse drug reactions (ADRs) affecting 
oncology patients and (B) Incidence of adverse drug reactions 
(ADRs) and degrees of toxicity in the Chemotherapy Clinic.
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(platinum compounds) (30.0%); 1 reaction related to an 
antithrombotic agent (vitamin K antagonist) (10.0%); 1 
reaction to an antibacterial (glycopeptide antibacterial) 
(10.0%); 1 reaction to an antimycotic agent for systemic 
use (antibiotics) (10.0%), and 1 to a cytotoxic antibiotic 
and related substances (other cytotoxic antibiotics) (10.0%).
The mechanism of 8 (80.0%) of the reactions was of 
the type B. In terms of severity, there was no fatal reaction; 
4 reactions (40.0%) were classified as severe because 
they directly threatened the life of the patient; 3 reactions 
(30.0%) changed their normal activities and/or caused 
hospitalization and were classified as moderate, and 3 
(30.0%) were classified as mild, as they corresponded to 
unimportant reactions, since they did not substantially 
affect the patient’s life. Regarding causality, only 1 
reaction (10.0%) was classified as defined, 3 (30.0%) 
were probable, 6 (60.0%) possible, and no reaction was 
classified as doubtful.
Therefore, the pattern observed was a type B reaction, 
severe and primarily affecting males; the pharmacological 
groups that caused the reactions were the plant alkaloids 
and other natural products (podophyllotoxin derivatives 
and primarily taxanes) and other antineoplastic agents 
(platinum compounds).
Incidence of ADRs and Degrees of Toxicity in the 
Chemotherapy Clinic
One hundred and two patients were interviewed, 
of whom 61 were men (59.8%). The average age 
corresponded to 55.9 ± 14.9 years (minimum age: 17 
years, maximum age: 82 years). Gastrointestinal cancer 
and treatment with FLOX (oxaliplatin + fluorouracil + 
leucovorin) were the most frequent cases encountered 
(Table III). The data showed that patients with sarcomas, 
nerve tissue cancer, and head and neck cancer were those 
TABLE I - Description of spontaneous notifications of adverse drug reactions (ADRs) presented by oncology outpatients and 
inpatients from January to December 2010, Pharmacovigilance Sector (drug group; drug name; and disease and drug use)
Notification Drug Group Drug(s) involved Disease and drug use
1
B01AA 
Antithrombotic agent (vitamin K 
antagonists) 
Warfarin 
(B01AA03)
Multiple Myeloma. Prophylaxis of 
thrombotic event
2
J01XA 
Other antibacterials (glycopeptides 
antibacterials)
Vancomycin 
(J01XA01)
Acute Myeloid Leukemia. Febrile 
Neutropenia
3
J02AA 
Antimycotics for systemic use 
(antibiotics)
Amphotericin B 
(J02AA01)
Acute Myeloid Leukemia. 
Filamentous fungus infection
4
L01CB 
Plant alkaloids and other natural 
products (podophyllotoxin 
derivatives)
Etoposide (PEB regimen: cisplatin, 
etoposide, and bleomycin) 
(L01CB01)
Malignant neoplasm of testis
5 L01CD 
Plant alkaloids and other 
natural products (taxanes)
Paclitaxel (monochemotherapy) 
(L01CD01)
Kaposi’s sarcoma
6
Docetaxel (monochemotherapy) 
(L01CD02)
Malignant neoplasm of prostate
7
L01DC 
Cytotoxic antibiotics and related 
substances (other cytotoxic 
antibiotics)
 Bleomycin (ABVD regimen: 
doxorubicin, bleomycin, vinblastine, 
and dacarbazine) 
(L01DC01)
Hodgkin’s Lymphoma
8
L01XA  
Other Antineoplastic agents 
(platinum compounds)
Cisplatin (monochemotherapy) 
(L01XA01) 
Malignant neoplasm of the oral cavity
9
Cisplatin (regimen: cisplatin, 
doxorubicin, methotrexate) 
(L01XA01) 
Malignant neoplasm of bone
10 Carboplatin (regimen: carboplatin 
and paclitaxel) (L01XA02)
Malignant neoplasm of ovary
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TABLE II - Description of spontaneous notifications of adverse drug reactions (ADRs) presented by oncology outpatients and 
inpatients from January to December 2010, Pharmacovigilance Sector (patient age; gender; description of the reaction; and 
classification according to the mechanism, causality, and severity)
Notification Patient age 
and gender
Description of the reaction Classification according to the 
mechanism, causality, and severity
1 59 years 
Female
Ecchymosis, petechiae without rectal or mucosa 
bleeding, and coagulopathy
Type A, possible, and severe 
2 43 years 
Male
Severe urticarial reaction (skin rash, itching, and 
fever)
Type B, probable, and moderate
3 61 years 
Female
Tremors, tachycardia, and oxygen saturation during 
infusion 
Type B, probable, and moderate
4 19 years 
Male
Exaggerated hypersensitivity reaction at the 
beginning of the infusion of etoposide (1st cycle)
Type B, probable, and severe
5 64 years 
Male
Swelling at the infusion site Type B, definite, and mild
6 70 years 
Male
Blackish pigmentation on vein where the medication 
was infused
Type B, probable, and mild
7 24 years 
Male
Stevens–Johnson syndrome Type B, probable, and severe
8 35 years 
Male
Orange pigmentation in nails (onychopathy) Type B, probable, and mild
9 23 years 
Male
Acute kidney injury (AKI) Type A, possible, and moderate
10 68 years 
Female
Anaphylaxis during administration of carboplatin 
(10th cycle)
Type B, probable, and severe
TABLE III - Neoplasms, antineoplastic protocols, and adverse drug reactions (ADRs) of outpatients interviewed in the Chemotherapy 
Clinic from October to November 2010
Neoplasms and Antineoplastic protocols Number of patients Percentage (%) ADRs per patient (mean)
Gastrointestinal Cancer 67 65.7 3.4
FLOX 23 22.5 2.8
5-FU/LV 16 15.7 3.1
IFL Saltz 12 11.8 4.3
IFL Saltz + Bevacizumab 5 4.9 4.2
CDDP + Gencitabin 3 2.9 2.7
CDDP + Docetaxel 2 1.9 8.5
Bevacizumab (a) 1 1.0 3.0
Carboplatin + Paclitaxel 1 1.0 2.0
IFL Saltz + Cetuximab 1 1.0 4.0
Cetuximab + Irinotecan 1 1.0 4.0
CDDP + Etoposide 1 1.0 3.0
Gencitabin 1 1.0 5.0
Head and Neck Cancer 8 7.8 5.1
CDDP 4 3.9 4.5
Carboplatin + Paclitaxel 2 1.9 6.5
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Neoplasms and Antineoplastic protocols Number of patients Percentage (%) ADRs per patient (mean)
Carboplatin 1 1.0 2.0
Methotrexate 1 1.0 8.0
Cancer of the Genitourinary Tract 7 6.7 3.6
PEB 3 2.7 2.0
CDDP + Etoposide 1 1.0 4.0
VIP 1 1.0 4.0
Docetaxel 1 1.0 4.0
Docetaxel + Zoledronic acid 1 1.0 7.0
Cancer of the Respiratory Tract 6 5.9 4.8
Carboplatin + Paclitaxel 4 3.9 3.7
Carboplatin + Gencitabin 1 1.0 7.0
CDDP + Etoposide 1 1.0 7.0
Sarcomas 5 4.9 5.8
CDDP + Doxorubicin 2 1.9 7.5
Ifosfamide 1 1.0 7.0
Paclitaxel 1 1.0 5.0
CAV + IFO/VP 1 1.0 8.0
Skin Cancer 3 3.0 3.0
CVD 3 3.0 3.0
Nerve Tissue Cancer 3 3.0 5.7
Doxorubicin + Ifosfamide 1 1.0 6.0
IFO/VP 1 1.0 6.0
Ifosfamide 1 1.0 5.0
Gynecological Cancer 3 3.0 4.0
Carboplatin + Doxorubicin 2 2.0 4.0
Trastuzumab 1 1.0 4.0
Legend: FLOX: oxaliplatin + fluorouracil + leucovorin; 5-FU/LV: fluorouracil + leucovorin; IFL Saltz: irinotecan + fluorouracil 
+ leucovorin; CDDP: cisplatin; PEB: cisplatin + etoposide + bleomycin; VIP: etoposide + ifosfamide + cisplatin; IFO/VP: 
ifosfamide + etoposide; CVD: cisplatin + vimblastine + dacarbazine; CAV: cyclophosphamide + doxorubicin + vincristine. (a) In 
this protocol, the patient also uses capecitabine (oral antineoplastic).
TABLE III - Neoplasms, antineoplastic protocols, and adverse drug reactions (ADRs) of outpatients interviewed in the Chemotherapy 
Clinic from October to November 2010 (cont.)
with more ADRs (5.8, 5.7, and 5.1 ADRs per patient, 
respectively), as well as patients treated with CAV + 
IFO/VP (cyclophosphamide/doxorubicin/vincristine + 
ifosfamide/etoposide) and methotrexate (either with 8.0 
ADRs per patients).
Some protocols include treatment with concomitant 
radiotherapy. Leucovorin and zoledronic acid mentioned 
above, although not antineoplastic agents, are present 
in some protocols. Leucovorin is used together with 
fluoropyrimidines, such as fluorouracil, to potentiate the 
therapeutic effects of these drugs. The zoledronic acid is 
used in the treatment of tumor-induced hypercalcemia 
and in patients with advanced malignant tumor with 
bone involvement or metastases. Other medications 
are also administered in intravenous drips during the 
chemotherapy session to reduce possible reactions, 
such as metoclopramide, ondansetron, dexamethasone, 
electrolyte replacers, ranitidine, diphenhydramine, mesna, 
and mannitol.
Table IV shows the incidence of ADRs reported by 
patients, which occur during and after the chemotherapy 
session. Nausea (59.8%), alopecia (46.1%), fatigue (46.1%), 
diarrhea (39.2%), and taste disturbance (31.4%) were the 
five most reported reactions in the Chemotherapy Clinic.
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TABLE IV - Incidence of adverse drug reactions (ADRs) reported 
by outpatients on antineoplastic treatment at the Chemotherapy 
Clinic from October to November 2010
ADRs Number of patients Percentage (%)
Nausea 61 59.8
Alopecia 47 46.1
Fatigue 47 46.1
Diarrhea 40 39.2
Taste Disturbance 32 31.4
Vomiting 31 30.4
Insomnia 29 28.4
Dizziness 28 27.4
Obstipation 25 24.5
Pain 23 22.5
Mucositis 23 22.5
Dyspepsia 21 20.6
Drowsiness 20 19.6
Fever 17 16.7
Tremor 12 11.8
Hiccups 10 9.8
TABLE V - Distribution of patients according to the degree of toxicity of the adverse drug reactions (ADRs) presented by outpatients 
of the Chemotherapy Clinic from October to November 2010 (National Cancer Institute Common Terminology Criteria for Adverse 
Events, CTCAE, version 3) 
ADRs Number of patients
Percentage (%)
Grade 1 Grade 2 Grade 3 Grade 4
Nausea 61 60.7 29.5 9.8 0.0
Fatigue 47 46.8 31.9 2.1 19.2
Diarrhea 40 52.5 25.0 17.5 5.0
Vomiting 31 38.7 29.0 29.0 3.3
Dizziness 28 78.6 17.9 3.6 0.0
Obstipation 25 68.0 20.0 12.0 0.0
Dyspepsia 21 71.4 23.8 4.8 0.0
dizziness, and fatigue) into different degrees of toxicity 
(Table V), it was observed that 57.7% of the symptoms 
were of toxicity grade 1, 26.5% were grade 2, 11.1% were 
grade 3, and 4.7% were grade 4, but some of the symptoms 
investigated do not have grade rating 4.
DISCUSSION
Under-reporting is recognized as a major limitation 
of the spontaneous ADR reporting system (Gonzalez-
Gonzalez et al., 2013), and may be the result of fear on the 
part of health professionals to formalize the occurrence, 
fear of punishment, difficulty in completing the form, or 
lack of understanding of what constitutes an ADR. In the 
review by Lopez-Gonzalez et al., (2009), factors including 
ignorance (only severe ADRs need to be reported), 
diffidence (fear of appearing ridiculous for reporting 
merely suspected ADRs), lethargy (lack of interest or time 
to find a report card, and other excuses), and insecurity (it 
is nearly impossible to determine whether or not a drug 
is responsible for a particular ADR were some causes 
of under-reporting. The current study demonstrated that 
notifications of ADRs per year in oncology patients are a 
very small number, especially considering the toxicity of 
chemotherapy, thus characterizing the under-reporting. 
Another study showed that 89 reactions caused by 
antineoplastic drugs were reported within one year. It 
was also realized in a tertiary care teaching hospital in a 
developing country and with outpatients and inpatients; 
however, the hospital had 1,400 beds, there were 258,119 
patients who were admitted and those who visited the 
hospital as outpatients during the study period. The 
pharmacovigilance service included clinical pharmacists, 
and the information regarding the ADRs reported in 
the unit was periodically disseminated to health care 
Based on this analysis, oncology patients on 
antineoplastic treatment feel 3.8 ± 2.4 symptoms on 
average, with a range of 0–10 reactions. Among the 102 
patients analyzed, 9 (8.8%) reported no reaction, 13 
(12.7%) had only one reaction, 8 (7.8%) had 2 reactions, 
14 (13.7%) had 3 reactions, 19 (18.6%) had 4 reactions, 38 
(37.3%) had 5 to 9 reactions, and only one patient (1.0%) 
showed 10 reactions (treated with cisplatin + docetaxel).
When the ADRs investigated were classified 
(nausea, vomiting, diarrhea, constipation, dyspepsia, 
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professionals of the hospital through a news bulletin 
that published twice in a year. Nevertheless, the authors 
reported the occurrence of under-reporting (Jose, Rao, 
2006). 
There are no studies analyzing the pattern of 
reactions reported by spontaneous notifications with an 
emphasis in oncology. However, studies by Mallik et 
al., (2007) and Prasad et al., (2013) analyzed the pattern 
of ADRs to chemotherapy in cancer inpatients admitted 
retrospectively and prospectively, respectively, which 
corroborated with the current results. Mallik et al., (2007) 
found a greater number of ADRs in men, between 61 and 
70 years old (mean age 57.8 ± 11.5 years old), primarily 
administered cisplatin. Prasad et al., (2013) found similar 
results; most ADRs occurred in men, aged between 50 and 
59 years old, on cisplatin therapy and were classified as 
probable through the Naranjo Algorithm.
There is a large standoff to identify the definite 
causality in oncology by the very structure of the Naranjo 
Algorithm. Several drugs are used concomitantly with 
the suspect medication; for example, 4 reactions to 
antineoplastic treatment occurred in patients on multidrug 
therapy. Also, patients have, in addition to cancer, other 
underlying diseases that end up confusing the diagnosis of 
ADR. Another standoff on proving the causal relationship 
is the determination of the plasma concentration of the 
drug, since therapeutic monitoring is not common. Even 
with the administration of therapeutic doses, plasma levels 
can be altered by deviations in product quality, genetic 
polymorphism, exaggerated sensitivity of the target tissue, 
drug interactions, and hepatic and renal dysfunctions. In 
contrast, no reaction was classified as doubtful, since many 
are described in the literature and package insert, such as 
vancomycin and urticarial reaction (Perrin-Lamarre et 
al., 2010), cisplatin and nephrotoxicity (Yao et al., 2007), 
carboplatin and anaphylaxis (Iwamoto et al., 2012), 
bleomycin and Stevens-Johnson syndrome (Giaccone et 
al., 1986), and etoposide and hypersensitivity reaction 
(Lindsay, Gaynon, 2012).
The two type A reactions have well-established 
mechanisms of reaction and are easier to classify as 
definite. However, in the case of warfarin, it was classified 
as possible because the patient, in addition to have 
undergone a nephrectomy, was concurrently treated with 
dexamethasone, whose interaction may result in increased 
risk of bleeding and abnormal coagulation (Klasco, 2013). 
Thus, the event presented may not have been an ADR 
but a consequence of drug interactions and/or decreased 
excretion of warfarin.
Because the type A reactions are predictable, 
reversible, treated with dose adjustments and can 
be avoided, the role of the clinical pharmacist gains 
importance. The notifications that include type A reaction 
demonstrate a clear need for a clinical pharmacist to 
monitor the patients. In the case of warfarin, inspecting 
the drug interactions before use would be necessary, 
and could lead to a reduction in the dose of warfarin to 
50% for 4 days (Klasco, 2013), in addition to regular 
assessment of renal function and suitable dose adjustment. 
In the case of AKI induced by cisplatin, the pharmacist 
should be aware of the patient’s renal function before 
administration of the antineoplastic, ensure that the patient 
is adequately hydrated and should guide the patients to 
increase fluid intake 24h before and after chemotherapy, 
increase the amounts of antioxidants in food or vitamin 
supplementation, as well as propose protocols for the 
prevention and treatment of nephrotoxicity based on 
antioxidant drugs, and based on the mechanism of toxicity 
of cisplatin (Hsu, Guo, 2002; Miller et al., 2010).
With respect to the type B reactions, though they are 
unpredictable and of unknown mechanism of reaction, the 
pharmacist must be aware, for example, of previous exposure 
to platinum compounds, ensuring that corticosteroids and 
antihistaminics are administered prior to the infusion of 
the drug to prevent hypersensitivity reactions (Cortijo-
Cascajares et al., 2012). In addition, the pharmacist should 
warn the patients about the hyperpigmentation reaction, and 
advice against exposure to the sun.
The five most reported reactions identified in the 
Chemotherapy Clinic (nausea, alopecia, fatigue, diarrhea, 
and taste disturbance) are conform to those reported by 
Lau et al. (2004), who also investigated the most frequent 
reactions in oncology patients, except taste disturbance 
that was not measured by these researchers. The ten most 
common ADRs reported by Lau et al. (2004), included 
constipation, nausea with or without vomiting, fatigue, 
alopecia, drowsiness, myelosuppression, skin reactions, 
anorexia, mucositis, and diarrhea. The current study also 
showed that patients with sarcomas, nerve tissue cancer, 
and head and neck cancer showed more ADRs, as well as 
patients treated with CAV + IFO/VP and methotrexate.
Chemotherapy-induced nausea and vomiting 
(CINV) are the most feared and the most common 
symptoms that affect the quality of life, as the patient’s 
routine is significantly affected by these symptoms, thus 
justifying the need for their effective management by 
health professionals. Iihara et al. (2011) demonstrated 
that pharmaceutical intervention to facilitate the use of 
antiemetics in the prophylaxis of CINV has a favorable 
result, i.e., increased number of patients with complete 
response at the acute and late phases of CINV. Cisplatin 
has a known high emetogenic potential (>90% of risk) 
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(Hesketh et al., 1997). Therefore, it is important to avoid 
CINV, the antiemetic administration before (30 minutes 
before infusion of the antineoplastic agent) and after the 
chemotherapy session (3 days), from the first treatment 
cycle before the onset of the effect, and not just after 
nausea and vomiting, as frequently occurs in clinical 
practice. Highly emetogenic chemotherapy patients 
should be treated with the combination of the three 
agents for the prevention of acute and delayed CINV; an 
antagonist of the 5-HT3 receptor, dexamethasone and an 
antagonist of the NK1 receptor (aprepitant) (American 
Society of Clinical Oncology et al., 2006). Patients 
should also adopt non-pharmacological measures, such 
as avoid foods with a strong taste/odor, foods with excess 
fat, carbonated beverages, in addition to the stimulation 
of a hyperfractionated diet and oral hygiene (Rhodes, 
McDaniel, 2001).
Alopecia negatively affects the appearance, body 
image, sexuality, and self-esteem. Patients and family 
members often think that all individuals undergoing 
antineoplastic treatment will manifest this reaction. In 
this study, alopecia was the second most frequent effect; 
however, less than half of the patients presented it. This 
finding contradicts data found in the literature, where 
the estimated incidence for alopecia is 65% and is the 
third most frequent toxicity in cancer patients (Trueb, 
2009). Adequate management practices can prevent and 
mitigate this adverse effect and increase the quality of 
life of oncology patients (Wang et al., 2006); however, 
the studied patients did not receive any intervention for 
alopecia. The low frequency observed in this study may 
be attributable to the fact that most patients were treated 
with 5-FU and oxaliplatin, which cause alopecia in low 
proportions (Trueb, 2009; Furue, 2005).
Fatigue affected almost half of the patients in 
this study and was the most severe symptom because 
some patients were confined to bed after a session of 
chemotherapy (grade 4 toxicity). The patients received 
no intervention for fatigue; however, they required 
appropriate management to reduce the frequency and 
severity of this reaction. There is still no consensus on 
the best treatment for fatigue. Based on a review (Payne 
et al., 2012), 116 studies administered pharmacological 
and non-pharmacological interventions related to the 
management of fatigue and weight loss in cancer patients, 
with the administration of eicosapentaenoic acid (EPA) 
being the primary pharmacological intervention and 
physical exercise and psychosocial support the main 
nonpharmacological intervention. Methylphenidate, 
modafinil, l-carnitine, and corticosteroids are other drugs 
useful in the treatment of fatigue, although there is not 
much supporting evidence (Sarhill et al., 2001; Morrow 
et al., 2005; Gramignano et al., 2006; Hanna et al., 2006; 
Haq, Butt, 2007).
Diarrhea occurs because the epithelial cells of the 
gastrointestinal tract are destroyed by certain antineoplastic 
agents, such as fluorouracil and irinotecan, which results 
in poor digestion and absorption of nutrients (Shafi, 
Bresalier, 2010). In this study, diarrhea was the fourth most 
commonly reported ADR. When the patients developed 
this reaction, loperamide was administered. Loperamide 
has been recognized as a more effective pharmacological 
agent for treating diarrhea (Shafi, Bresalier, 2010; Benson 
et al., 2004), and its use should be adequately monitored.
Taste disturbance, such as hypogeusia (moderately 
altered taste), ageusia (loss of taste), and dysgeusia 
(change in taste), was the fifth most reported effect on 
outpatients of the Chemotherapy Clinic. This reaction is 
very common in individuals undergoing chemotherapy 
and culminates in loss of appetite and weight loss, 
including the anorexic condition. This weight loss caused 
by taste disturbance also leads to fatigue, as previously 
mentioned. Taste disturbance should be adequately treated 
so that patients are not affected by other morbidities 
that are caused by this reaction, as exposed. There 
are few effective pharmacological measures for taste 
disturbances, although reports suggest that vitamin D 
may have some beneficial effect in dysgeusia (Moser et 
al., 2011); however, pharmacological interventions are 
not administered at the study institution and management 
is mainly based on non-pharmacological measures that 
include dietary adjustments and oral hygiene.
As observed in the present study, there were grade 
3 and 4 ADRs associated with chemotherapy, although 
most patients reported grade 1 symptoms. The Brazilian 
Society of Oncology Pharmacists (SOBRAFO) and the 
Brazilian National Agency for Sanitary Surveillance 
(ANVISA) recommend that all grade 3 and 4 reactions 
in oncology should be reported (Sobrafo, Anvisa, 
2011). However, these reactions have not been notified 
in the Pharmacovigilance Sector of the hospital, which 
demonstrates that the healthcare professionals are 
not prepared to notify ADRs, even being a hospital 
integrated with the Pharmacovigilance Program of 
ANVISA. They do not possess a full understanding of 
the diagnosis of ADRs and the criteria to notify them, 
among other reasons already observed by Lopez-Gonzalez 
et al. (2009). A periodic training on spontaneous ADR 
reporting and pharmacovigilance must be provided for 
multidisciplinary team involved with the cancer care. The 
Pharmacovigilance Sector could also begin to implement 
the active surveillance for ADRs; the pharmacist could 
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gather information on ADRs directly from a patient, a 
physician, or by reviewing medical records; trigger tools 
can be used for this process. News bulletins published 
by pharmacovigilance departments of hospitals and an 
individual feedback to reporters could also be an effective 
strategy for improving pharmacovigilance.
Thus, the pharmacist should actively participate in 
pharmacovigilance in oncology following the onset of 
ADRs to the treatment, recording grade 3 and 4 reactions 
in the pharmacovigilance systems, providing guidance for 
the rational use of medicines as well as pharmacological 
and non-pharmacological measures, developing guidelines 
for the prevention and treatment of ADR, and health 
education. The pharmacist must always be attentive so 
that ADRs are minimized during treatment.
CONCLUSIONS
This study has shown that pharmacovigilance is 
an increasingly important science in the hospital setting, 
especially in the oncology field. However, educating 
the health professionals about the need to notify these 
reactions is more important than studying ADRs. It was 
observed that oncology patients present several ADRs, 
including grade 3 and 4, which should be reported in 
the pharmacovigilance system. However, these pass by 
unreported, which contributes to the under-reporting in 
oncology. The training of health professionals working 
in hospitals on how, when and what to notify is essential 
to reduce under-reporting. In addition, it is proposed that 
a clinical pharmacist should be recruited in this process, 
as they are ideal professionals to efficiently perform the 
pharmacovigilance role. The present paper can also be 
used to educate patients, to demonstrate that there are 
many ADRs associated with chemotherapy, but most of 
these are not debilitating; thus adherence to antineoplastic 
treatment can be improved.
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